- Home
- CRML vs ORIC Comparison
CRML vs ORIC Comparison
Compare CRML & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRML
- ORIC
- Stock Information
- Founded
- CRML N/A
- ORIC 2014
- Country
- CRML United States
- ORIC United States
- Employees
- CRML N/A
- ORIC N/A
- Industry
- CRML
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- CRML
- ORIC Health Care
- Exchange
- CRML NYSE
- ORIC Nasdaq
- Market Cap
- CRML 298.8M
- ORIC 362.9M
- IPO Year
- CRML N/A
- ORIC 2020
- Fundamental
- Price
- CRML $2.96
- ORIC $10.71
- Analyst Decision
- CRML
- ORIC Strong Buy
- Analyst Count
- CRML 0
- ORIC 9
- Target Price
- CRML N/A
- ORIC $18.29
- AVG Volume (30 Days)
- CRML 7.7M
- ORIC 987.5K
- Earning Date
- CRML 02-01-2025
- ORIC 08-11-2025
- Dividend Yield
- CRML N/A
- ORIC N/A
- EPS Growth
- CRML N/A
- ORIC N/A
- EPS
- CRML N/A
- ORIC N/A
- Revenue
- CRML $476,979.00
- ORIC N/A
- Revenue This Year
- CRML N/A
- ORIC N/A
- Revenue Next Year
- CRML N/A
- ORIC N/A
- P/E Ratio
- CRML N/A
- ORIC N/A
- Revenue Growth
- CRML 326.80
- ORIC N/A
- 52 Week Low
- CRML $1.23
- ORIC $3.90
- 52 Week High
- CRML $11.25
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- CRML 55.19
- ORIC 67.12
- Support Level
- CRML $2.82
- ORIC $10.42
- Resistance Level
- CRML $3.88
- ORIC $11.14
- Average True Range (ATR)
- CRML 0.49
- ORIC 0.59
- MACD
- CRML -0.01
- ORIC -0.08
- Stochastic Oscillator
- CRML 48.60
- ORIC 79.49
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.